Abstract Background: Basic research toward understanding and treating disc pathology in the spine has utilized numerous animal models, with delivery of small molecules, purified factors, and genes of interest. To date, gene delivery to the rat lumbar spine has only been described utilizing genetically programmed cells in a matrix which has required partial disc excision, and expected limitation of treatment diffusion into the disc. Purpose: This study was designed to develop and describe a surgical technique for lumbar spine exposure and disc space preparation, and use of a matrix-free method for gene delivery. Methods: Naïve or genetically programmed isogeneic bone marrow stromal cells were surgically delivered to adolescent male Lewis rat lumbar discs, and utilizing quantitative biochemical and qualitative immunohistological assessments, the implanted cells were detected 3 days post-procedure. Results: Statistically significant differences were noted for recovery of the β-galactosidase marker gene comparing delivery of naïve or labeled cells (10 5 cells per disc) from the site of implantation, and between delivery of 10 5 or 10 6 labeled cells per disc at the site of implantation and the adjacent vertebral body. Immunohistology confirmed that the β-galactosidase marker was detected in the adjacent vertebra bone in the zone of surgical implantation. Conclusions: The model requires further testing in larger cohorts and with biologically active genes of interest, but the observations from the pilot experiments are very encouraging that this will be a useful comparative model for basic spine research involving gene or cell delivery, or other locally delivered therapies to the intervertebral disc or adjacent vertebral bodies in rats.
Introduction
Low back pain (LBP) is frequently caused by overexertion and muscular pain symptoms, with less common etiologies including degenerative "wear and tear" changes of the spine joints. LBP is already a leading cause of lost days at work, morbidity, and suffering with an economic burden of over $100 billion annually [7] , and all of these are expected to increase as the American "Baby Boomers" approach later life. The spine is composed of a basic functional unit, termed a motion segment, that has some specialized sites but is largely a repeated structure throughout. The motion segment includes the bony vertebral body, the bilateral diarthrodal facet joints, and the intervertebral disc (IVD). Facet joint arthrosis or other posterior element spine anomalies [13] and degenerative disc disease (DDD) [19] are well-documented LBP etiologies, prompting clinical management including physical therapy, oral and injection-based medical regimens, and for some patients, surgery [2, 16, 25] .
Basic research efforts have utilized comparative surgical models to develop methods to manage experimentally induced spine degeneration that may be translatable to clinical use in the near future. The well-described New Zealand White (NZW) rabbit needle-annulotomy model for DDD recapitulates clinical disc dehydration, height loss, and diminished proteoglycan production [17, 24] . Furthermore, experimental delivery of genes [21] or purified factors [18] to the NZW IVD has been shown to prevent or reverse IVD degeneration [1, 20] . Rodent disc needle-annulotomy models also show disc pressure changes and degeneration, which is rescued by growth and differentiation factor-5 (GDF-5) gene delivery with live adenovirus [6, 15] , suggesting the rescue of disc degeneration is generalizable and possibly clinically translatable. In an effort to avoid gene delivery with live recombinant virus vectors, ex vivo gene therapy utilizes implantation of genetically reprogrammed cells, minimizing risk for unintended virus spread and maximizing cell target infection and resultant gene expression. Rodent disc implantation with labeled or genetically programmed cells to date has only been described following partial IVD removal, and with cells implanted within a gelatin or collagen matrix [8, 14] , each drawbacks if injectiononly based therapies are desired. Matrix-free cell delivery is an important technique as suggested by the rabbit studies described above, and the use of matrix-free injectate for the human DDD trial being conducted with GDF-5 (Advanced Technologies and Regenerative Medicine) (http://clinicaltrials.gov/ct/ show/NCT00813813).
We aimed to develop a rat model for delivering matrixfree cells to the disc to study potential therapies for clinical problems like DDD. We describe a comparative model utilizing isogeneic Lewis rats involving an anterior lumbar spine surgical exposure, trans-vertebral body IVD endplate perforation, and delivery of naïve or recombinant adenovirus-infected bone marrow stromal cells to lumbar spine discs. We hypothesize that: (1) Intra-discal delivery of cells genetically programmed to express β-galactosidase will be detectable post-implantation, and their recovery will be dose dependent to the number of cells implanted, and (2) β-galactosidase-expressing cells will also be detectable in the vertebral body adjacent to the discs receiving cell implantations.
Materials and Methods
Recombinant adenovirus and cells for implantation were generated and characterized, and necropsy trial injections were performed. All animal experiments and primary cell cultures were performed under an IACUC-approved protocol. Bone marrow stromal cells (BMSCs) and the recombinant adenoviral (Ad) vector (Ad serotype 5-deficient in E1 and partially deficient in E3) encoding the lacZ transgene (β-galactosidase marker enzyme) were prepared as described previously [10] . Briefly, recombinant adenovirus was amplified in HEK293 cells, purified using cesium chloride density gradient ultracentrifugation, quantified and dosed on the basis of physical particle count. Male Lewis rats (n034 total, average weight 275-300 g) were used to minimize probability for immunological rejection of grafted cells. Bone marrow from n015 male Lewis donor rats was isolated by femora/tibiae intramedullary lavage with growth medium (DMEM low glucose, 10% fetal bovine serum, 1% penicillin/streptomycin, 0.1% fungizone), gentle mechanical homogenization with serological pipette, adsorption onto tissue culture plastic dishes overnight in growth medium, and expansion of adherent cells in culture (termed BMSCs). BMSC subcultures were genetically modified with 10 3 , 10 4 , 10 5 , or 10 6 particle units/cell of Ad-lacZ, transduced cultures were assessed for expression of β-galactosidase using X-gal staining [11] , and the optimal MOI for X-gal staining with minimal cell death was determined to be 10 5 (data not shown). Cells were Ad-lacZ or mock (no virus) infected for implantation experiments 18-24 h prior to the procedure. On the day of implantation, cells were trypsinized, pooled according to treatment and counted with a hemacytometer, concentrated by centrifugation, and suspended into a volume to allow delivery of either 10 5 or 10 6 cells in 25 μL; further concentration of cells into smaller injection volume was not technically possible. Donor rat necropsy dissection and mock implantations revealed the lumbar discs to only accept very small injectate volumes (less than or equal to 10 μL), and our implantation method was modified as described below to allow larger injection volumes.
Surgical cell implantation into the IVDs was performed, and spine specimens were recovered. Male Lewis rats (n0 19) were anesthetized with intraperitoneal ketamine/xylazine, the anterior abdomen was shaved and sterilely prepared, and the animals were subjected to a transperitoneal exposure of lumbar levels L4-L6, as previously described [8, 14, 22] . Vertebral endplates were punctured using a 22-Ga needle passed through the anterior L5 body proximally into the L4 body (through the L4/5 disc), and this process was repeated directed distally into the L6 body (through the L5/6 disc); two to three passages per disc were performed. Intraoperative high-definition X-rays were obtained with the 22-Ga needle crossing the L5/6 disc space to confirm segmentation (Faxitron model MX-20 with DC-4 digital camera, Faxitron X-Ray Corporation, Wheeling, IL) ( Fig. 1) . Using a 1-mL tuberculin syringe and 25-Ga needle, 20-30 μL of genetically modified or naïve BMSCs were delivered to L4/5 and L5/6 disc spaces (Fig. 2) , and the abdominal wound was closed in layers. Animals were revived and allowed ad libitum food, water, and activity. Postoperative pain was managed with subcutaneous buprenorphine ("Buprenex" 0.025 mg/kg each 12 h post-procedure days 0-2, and then as needed). Experimental groups used four to six animals per condition, and to allow sample independence, animals were implanted with the same treatment at both the L4/5 and L5/6 levels (naïve or Ad-lacZ-modified cells and either 10 5 or 10 6 cells per level). Animals were euthanized on the third postoperative day by carbon dioxide inhalation, and spines were collected.
Spines were processed for histology and β-galactosidase quantification. The spines were immediately dissected en bloc from L4 to L6. The L5/6 disc and cranial half of the L6 vertebral body were preserved as tissue specimens for biochemical quantification and were stored at −80°C. The L4 to L5 segments were fixed in 4% paraformaldehyde in codylate buffer, decalcified with 10% EDTA pH7.4, paraffin embedded, and analyzed by decalcified histology with trichrome stain and immunostaining with anti-β-galactosidase. The primary antibody was a mouse monoclonal IgG1 raised against bacterial β-galactosidase (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), and secondary was included in the Vectastain ABC kit (Vector Labs, Burlingame, CA). Naïve Lewis rat BMSCs had no anti-β-galactosidase immunoreactivity, and Ad-lacZinfected BSMCs demonstrated intense cytoplasmic immunostaining (data not shown). For the β-galactosidase quantifications, tissues recovered from the L5/L6 discs and the proximal L6 vertebral bodies were mechanically homogenized on ice, clarified by centrifugation at 4°C, and total protein normalized supernatants were biochemically quantified for β-galactosidase expression in triplicate using a commercially available β-galactosidase activity assay (Tropix Galacto-Light, Applied Biosystems, Bedford, MA) using an LMaxII 384 luminometer (Molecular Devices, Berthold Technologies, Wildbad, Germany). Sample expression levels were interpolated from a standard curve generated within each experiment and are reported as average±standard deviation. Due to small sample number and expected non-Gaussian data distribution, relative β-galactosidase signal intensities were compared using Mann-Whitney nonparametric statistics with significance set at p<0.05 (SPSS v16, SPSS Inc., Chicago, IL).
Results
Ad-lacZ-modified BMSCs were detectable in recovered spine tissues by histology and biochemical assessments. The oblique bone tunnel representing the needle passage performed for endplate perforation was observed by histology in decalcified sections, and anti-β-galactosidase immunostaining revealed intense expression within the bone tunnel in the Ad-lacZ treatment group, suggesting that at least a portion of the injectate delivered to the disc leaves the disc space and resides in the vertebral body. β-Galactosidase-expressing cells were not visualized in the disc space, potentially due to sectioning sampling artifact and the limited sample number. Biochemical β-galactosidase quantification from the L5/6 disc was 5-to 72-fold higher in the animals receiving Ad-lacZmodified cells than naïve cells delivered at either 10 5 cells/disc (p 00.018) or 10 6 cells/disc (p 00.021) ( Table 1) . β-Galactosidase expression in the L5/6 disc following naïve cell delivery at either 10 5 or 10 6 cells/disc was not different (p00.462), but was almost 22-fold higher for the 10 6 Ad-lacZ cells/disc delivery group (p 00.011). Accordingly, β-galactosidase expression in the cranial L6 vertebral body bone was quantified only for the 10 6 cells/disc implantations and showed almost 19-fold higher expression in the Ad-lacZ than naïve cell groups (p00.043).
Discussion
The present pilot study was conducted to assess the feasibility of delivering cells to rat lumbar discs and detecting those cells post-implantation to establish a comparative model for assessment of potential disc or vertebral body gene delivery therapies.
There are several limitations to the current study. As a pilot study, small animal numbers were used to make determinations regarding implanted cell dosing and the ability to detect evidence of the implanted cells. Further use of the model with larger animal numbers in the groups and with delivery of therapeutic genes of interest is indicated. For the purpose of detecting our biomarker, we utilized a very short study time interval; longer follow-up times utilizing the model are needed to demonstrate the animals' overall tolerance of the procedure and possible delayed disc degeneration induced by the endplate and/or annulus fibrosus needle punctures used. In relation to the disc volume, the injection volume used is large and spreads from the disc to the adjacent vertebral bodies, raising concerns for bone effects of the treatments delivered and possible systemic embolization due to passage into the vertebral endosteal space. Finally, we have utilized naïve and β-galactosidase-expressing cells, but biologically relevant genes need to be assessed in future longer time course studies, including BMP-7/OP-1, BMP-2, and GDF-5. Further study with the model is planned, with endpoints to include assessments of the adjoining vertebrae for treatment effects and for assessment of distal sites, including the lungs and liver.
Endplate perforation prior to cell implantation was chosen out of necessity to accommodate the injectate volume required to deliver the cell numbers utilized (10 5 and 10 6 per disc) and allowed a portion of the injection delivered to the disc to be observed in the adjacent vertebral bodies experimentally. Gene delivery with ex vivo genetic programming was chosen to maximize cell infection and expression of the β-galactosidase marker gene and to make identification of implanted modified cells more reproducible. Isogeneic Lewis rats were used to minimize immunoreactivity at the implantation site, and a 3-day time point for marker recovery was used as previously described [10] . We have shown that genetically modified cells can be efficiently delivered and detected in the Lewis rat disc space and adjacent vertebral bodies without a matrix, suggesting this to be a potentially useful comparative rodent model for gene delivery-based research for the disc or vertebral body.
Previous reports delivering labeled cells to the rat lumbar disc space have utilized matrices to allow the cells to be more easily handled and localized. In these studies, cells were cultured and labeled in vitro and then implanted. Gruber et al. [8] described the adsorption of labeled cells onto Gelfoam® and then re-implantation of the cell/matrix complex into the L4-7 disc spaces after partial anterior annulus removal. They described that creation of deeper cavities within the disc graft site improved maintenance of graft position and that they were able to detect presence of labeled cells with immunohistology in the annulus fibrosus and nucleus pulposus. They did not comment on detection of labeled cells in the adjacent vertebral bone, nor at other unintended locations. Leo et al. [14] described infection of disc, adipose, or bone marrow-derived cells labeled with recombinant Ad-luciferase and implantation into the L3/4 discs in an alginate matrix after partial anterior disc removal. They argued that the use of the alginate matrix helped to localize the implanted cells and better promoted a cartilagelike phenotype of the cells comparable to those of the native disc. They were able to detect the luciferase signal using in vivo bioluminescence imaging of animals at multiple time points and showed luciferase expression in transduced cells delivered to the disc. However, at 2 weeks post-procedure, they also detected luciferase in the liver and lungs in a few of their animals, possibly suggesting systemic circulation of the gene products. Neither study assessed the potential effect of differential implant cell dosing, nor did they describe the detection of implanted cells in the adjacent vertebral bones. Our current study utilizes treatment delivery without need for a matrix and no requirement for mechanical removal of disc material, and we have demonstrated ability to deliver and detect marker-modified cells in the disc implantation site and adjacent vertebral bodies. Our matrix-free delivery technique will not require endplate puncture in larger animal models, where injectate volumes can be larger, and more closely reflect the techniques used currently in clinical intervertebral disc instrumentation such as discography and the GDF-5 intra-discal injection clinical trial. Anterior annulus and vertebral endplate puncture in the current model may induce iatrogenic disc degeneration. The 25-Ga needle was chosen for the anterior annulotomy empirically, following brisk trituration of BMSCs through needles of differing caliber and assessment of resultant cultures for cell attachment and for the relative amount of debris generated. The 22-Ga needle for endplate puncture was chosen as the narrowest diameter needle capable of reproducibly tolerating the forces required for the maneuver without bending. Elliott et al. have reported that in rats, annulotomy with a 27-Ga needle leads to altered in vitro mechanical properties of lumbar discs, a finding which may predispose them to degenerate in vivo, as described for mouse [15] and rabbit [17, 24] models of needle annulotomy, and also following clinical discography [4] . Similar disc degeneration has been reported for comparative in vivo and in vitro models following experimental endplate damage [9, 12, 23] . The technique described and used for the current study involves both needle annulotomy and endplate trauma, and thus may predispose the animals to iatrogenic disc degeneration. Degeneration of the instrumented discs has not been observed to date, but the 3-day post-procedure follow-up is expected to be much too short to observe degenerative changes. Examination of implanted discs at later time points will be required in future studies using our model to determine the potential degenerative impact that the needle trauma induces and the possible impact of therapies delivered to control the degeneration.
Intervertebral disc needle annulotomy is unavoidable for our model if cells are to be surgically implanted, and the endplate perforation is also required due to the small rat disc volume to accept the injection. Practical limiting factors for disc injections as utilized in this model are: (1) the concentration of cells to be injected and (2) the volume of injectate that the disc can receive. With the culture generation, feeding, infection, and harvest methods described here, we have been able to concentrate 1-2×10 6 cells (a confluent 150-mm tissue culture plate) into a volume of 10-15 μL, which then is mixed into a cell slurry totaling 20-30 μL using growth media for suspension. Use of cells that concentrate more efficiently may allow injectate volumes to be reduced. Elliott et al. have reported average anatomic disc area and height measurements, resulting in estimates for lumbar disc volumes to be between 5 to 6.9 mm 3 [5] . Prior injections into the rat lumbar disc have ranged from 1 or 2.5-μL volumes [3] , up to 10 μL [14] . The latter would have been expected to not be contained in the disc and may explain the authors' report detecting biomarker external to the disc space receiving the implant [14] . Future use of our model will require assessment for distant circulation of implanted cells and lumbar disc volume descriptions by segment.
The current pilot study suggests that treatments can be delivered to the rat disc and adjacent vertebral bodies without a matrix, and can be reliably detected post-implantation. The described method may be a good means to study candidate therapies for disc degeneration, spine osteoporosis, or anterior spine fusion. Further investigation is indicated to better describe the model, particularly at later time points, and to assess candidate treatments or genes of interest as regards gene delivery-based investigation.
